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MeK’ing the Most of p53 Reactivation 
Therapy in Melanoma
John T. Lee1 and Meenhard Herlyn1
Melanoma is one of the few tumor types in which p53 is functionally repressed 
without extraneous mutations. With the number of kinase-based drug targets 
rapidly declining, p53 represents a relatively untapped resource for therapeutic 
intervention. Studies in other tumor types have demonstrated that reactiva-
tion of p53 is a viable strategy to initiate sustained tumor regression; combining 
p53 reactivation while inhibiting traditional genetic targets, such as mitogen-
activated protein kinase/extracellular signal–related kinase kinase (MeK), holds 
therapeutic promise.
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melanoma: current clinical outlook
The clinical success of vemurafenib 
(PLX4032) has underscored the impor-
tance of the mitogen-activated protein 
kinase (MAPK) signaling cascade in the 
initiation, progression, maintenance, 
and overall survival of malignant mela-
noma (Flaherty et al., 2010). Excitement 
surrounding this success is somewhat 
tempered by the eventual relapse of 
melanoma patients (median progres-
sion-free survival is 7 months). Thus, 
there remains a legitimate need for 
second-generation treatment options for 
patients whose disease will eventually 
recur while receiving vemurafenib.
A surge of recent reports has dem-
onstrated multiple mechanisms 
of acquired resistance to mutant-
specific inhibitors of B-Raf such as 
vemurafenib (Poulikakos and Rosen, 
2011). Upregulation of the insulin-
like growth factor receptor-1, de novo 
mutations in N-Ras, increased expres-
sion of the platelet-derived growth 
factor receptor-b, and increased 
activity of MAP3K8/Cot have been 
described as mechanisms employed 
by melanoma cells to bypass the pro-
apoptotic activities of this class of 
inhibitors. Related studies have also 
shown that intrinsic resistance to 
B-Raf inhibitors is largely contingent 
on the expression of PTEN, the nega-
tive regulator of the phosphoinositide 
3-kinase pathway (Gopal et al., 2010), 
suggesting that activation of this path-
way is sufficient to render melanoma 
cells innately resistant to mutant 
B-Raf inhibition. Collectively, these 
studies suggest that therapeutic regi-
mens that combine MAPK inhibition 
with pharmacological manipulation 
of alternative molecular circuitry will 
be necessary to achieve sustained 
responses in the clinic.
Status of p53 signaling in melanoma
The frequency of p53 mutations in mel-
anoma is dramatically lower than that 
in most other solid tumors, with inacti-
vating mutations seen in less than 10% 
of patients. In contrast to its tumor-
suppressive functions, p53, the “guard-
ian of the genome,” was originally 
reported to be overexpressed in mela-
noma (Albino et al., 1994). Subsequent 
studies, however, have demonstrated 
that p53 function is largely repressed in 
melanoma via several mechanisms: (i) 
overexpression or amplification of the 
negative regulator of p53, HDM2, and 
(ii) the loss or silencing of the CDK2NA 
locus that encodes Arf, an antagonist of 
HDM2 function (Bennett, 2008). These 
genetic events are seen in nearly 90% 
of patients with melanoma, suggesting 
that p53 inactivation plays a significant 
role in its etiology, despite the overt 
lack of mutations observed compared 
with many other tumor types.
In this issue, Ji et al., from Hensin 
Tsao’s group, report the results of 
sequencing performed across a large 
panel of cell lines to explore further 
the status of p53 expression in malig-
nant melanoma. They demonstrate that 
more than two-thirds of melanoma 
cell lines express wild-type p53; near-
ly 70% of p53 wild-type lines were 
shown to have genomic losses of the 
CDK2NA locus. In lines expressing 
mutant p53, 33% displayed similar 
losses, indicating that a large propor-
tion of melanoma cell lines selectively 
lose this locus during melanoma devel-
opment and/or in vitro establishment. 
These observations are supported by 
previous studies and underscore the 
critical role provided by ARF in modu-
lating control over the p53 signaling 
pathway.
p53 reactivation therapy: hope or hype?
Traditional chemotoxic therapies 
activate p53 function via the accu-
mulation of DNA damage and other 
stress-related pathways. The advent 
of targeted therapy introduced the 
notion of reactivating p53 in a non-
genotoxic manner, thereby restoring 
its tumor-suppressive capacity with-
out inducing additional mutations or 
unnecessary stress to the cell. Early 
attempts to restore p53 activity utiliz-
ing adenoviral vectors to deliver p53 
have demonstrated clinical efficacy 
and are under further investigation. 
More recent research has focused on 
pharmacological reactivation of p53 
through modulation of the activity of 
its multiple regulatory factors, includ-
ing SirT1/2, CRM1, and MDM2. The 
most prominent members of this class 
of effector compounds are the Nutlins, 
antagonists of the MDM2–p53 inter-
action that initiates the proteasomal 
degradation of p53. RG7112, the most 
promising Nutlin drug candidate, is 
undergoing clinical evaluation in both 
solid and nonsolid malignancies.
Ji et al. (2012) demonstrate in their 
work that the commercially available 
Nutlin-3 compound stabilizes p53 
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and increases its transcriptional activ-
ity. Additionally, they show that cell 
viability is most affected in melanoma 
cell lines expressing wild-type p53, 
as might be expected. The investiga-
tors subsequently hypothesized that, 
because the majority of melanoma 
patients harbor BRAF mutations yet 
express wild-type p53, this genotype 
(BRAFmut, p53wt) might best be targeted 
with a dual therapy involving MEK 
inhibition and p53 activation.
A therapeutic regimen in which 
inhibition of the MAPK cascade is 
combined with reactivation of p53 
in malignant melanoma is certainly 
predicated on well-established genet-
ic data. The MAPK signaling pathway 
is activated in nearly all melanomas, 
with the most prevalent activating 
mutations in BRAF, NRAS, and cKit. 
Likewise, as outlined above, nearly 
90% of melanomas express wild-type, 
but functionally impaired, p53. Based 
on these observations, the investigators 
treated ~40 cell lines with a known 
MEK inhibitor (U0126), Nutlin-3, or 
a combination of the two compounds 
to determine their additive, antagonis-
tic, or synergistic effects. The results 
from these studies demonstrated that 
~60% of melanoma cell lines exhibit 
some degree of synergy, whereas the 
remaining portion (38%) appear to 
have antagonistic effects after coad-
ministration of U0126 and Nutlin-3. 
The antagonism observed in such a 
large percentage of melanomas argues 
for additional studies to determine why 
such contrasting effects are exhibited 
within a single cancer type. Ji et al. 
suggest that prospectively genotyping 
patients should help stratify responders 
from nonresponders, but more explo-
ration is necessary to explain this phe-
nomenon.
Similar reports outlining the use 
of pharmacological p53 activators in 
melanoma have described a diverse 
response that can range from cell 
cycle arrest to induction of apoptosis 
to no response at all (Terzian et al., 
2010). To achieve measurable clinical 
responses in human patients, however, 
the general goal is to induce cell death 
or apoptosis consistently. Earlier data 
suggested that nearly two-thirds of 
melanoma lines responded favorably 
to combined MEK inhibition and p53 
activation; Ji et al. (2012) therefore 
investigated the induction of caspase 
activity and dependence of apoptotic 
induction on p53 after treatment with 
this same drug combination. Their 
results argue that the loss of viability 
observed in earlier experiments is due 
largely to a p53-dependent induction 
of caspase-3/7 activity. These data sup-
port the development of therapeutic 
strategies that target these pathways to 
achieve similar effects in humans.
mechanistic explanations
Melanoma is a bona fide example 
of a cancer exhibiting oncogene 
addiction, in which inhibition of 
the initiating oncogene kills trans-
formed cells. However, most studies 
investigating MEK inhibitors have 
described a cytostatic, rather than 
cytotoxic, effect when using this class 
of compounds (Haass et al., 2008). 
Furthermore, p53 reactivation in mela-
noma has been reported to inhibit cell 
cycle progression with only moder-
ate induction of apoptosis in selected 
cells (Terzian et al., 2010). Therefore, 
it is exciting to speculate about the 
mechanisms by which these gener-
ally cytostatic compounds become 
cytotoxic after concurrent administra-
tion. One plausible explanation is that 
MEK inhibition initiates transcriptional 
and posttranscriptional downregula-
tion of the HDM2 gene, leading to 
decreased HDM2 protein levels and 
increased p53 activity (Phelps et al., 
2005). Alternatively, other groups have 
reported that p53-mediated apop-
tosis is dependent on Arf, a protein 
encoded by the CDK2NA locus that 
is often deleted in malignant mela-
nomas, particularly in established 
cell lines such as those used in the 
current study (Junttila et al., 2010); it 
would therefore be intriguing to first 
stratify the melanoma lines based on 
their expression of the CDK2NA locus 
and then ascertain their single and 
combined responsiveness to these 
agents to help identify genetic-based 
prognostic indicators of response.
outlook and directions
Approximately 1 in 25 Americans 
will acquire some type of cancer in 
his or her lifetime; of these, a smaller 
percentage will be diagnosed with 
melanoma. The human body has 
a remarkable capacity to prevent, 
circumvent, and otherwise fight the 
initiation and progression of malig-
nancies, as evidenced by the 96% of 
the population who will die cancer 
free. This observation underscores the 
extraordinary success rate of tumor 
suppressors such as p53 to continually 
survey the body for biological stress-
es that ultimately damage DNA and 
selectively destroy those rogue cells.
Restoring the ability of p53 
in malignant cells is an exciting 
approach for melanoma and broader 
cancer therapeutics. Selectively target-
ing the kinome is highly regarded for 
its relevance in cancer, as well as its 
druggability; however, there are valid 
concerns surrounding the feasibility 
of selectively modulating transcription 
factors such as p53, including regu-
lation of essential downstream gene 
effectors. That said, there are a large 
number of nongenotoxic pharma-
cological activators of p53 in the 
Clinical Implications
•  Inhibition of the mitogen-activated protein kinase pathway  
through selective B-Raf inhibitors is effective, but responses are 
short lived; effective combinatorial therapies are warranted.
•  Other tumor models have convincingly demonstrated that 
nongenotoxic restoration of p53 activity in cells previously 
devoid of p53 function initiates dramatic tumor regression and/or 
senescence.
•  An array of pharmacological activators of p53 function have  
been identified and are currently undergoing preclinical and 
clinical evaluation.
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preclinical and clinical pipeline with 
multiple mechanisms of action (Chen 
et al., 2010) that may help discern the 
subtle nuances that ultimately dic-
tate the cellular outcome (cytostatic 
versus cytotoxic) to p53 reactivation. 
Combining such therapies with inhi-
bition of the MAPK pathway is logical 
and predicated on well-established 
clinical observations. Thus, Ji and 
colleagues’ report provides a solid 
platform on which future experimen-
tation can be devised to delve into 
the molecular circuitry that predicts 
responses to this type of therapy.
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It’s All about Position: The Basal Layer 
of Human epidermis Is Particularly 
Susceptible to Different Types of 
Sunlight-Induced DNA Damage
Gary M. Halliday1 and Jean Cadet2
In this issue, Tewari et al. show that although UVB most effectively causes 
cyclobutane pyrimidine dimers (CPDs) at the human epidermal surface, UVA-
induced CPDs predominate in the basal layer. Previous studies found higher 
accumulation of UVA-induced 8-oxo-7,8-dihydro-2′-deoxyguanosine and 
mutations in the basal layer. Therefore, the epidermal basal layer is particularly 
sensitive to UVA-induced genetic damage and the formation of mutations.
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Despite extensive research, the rela-
tive roles of different wavebands 
within sunlight in causing skin cancer 
in humans are unresolved. Most likely 
all wavebands contribute, although 
whether they each initiate similar or 
different biological responses involved 
in carcinogenesis such as mutagenesis, 
suppression of immunity, apoptosis, 
and disruption to cell cycle control is 
unknown. UVB (290–320 nm), UVA2 
(320–340 nm), and UVA1 (340–400 
nm) may all damage similar biologi-
cal systems, including DNA as a main 
target, and therefore have cumulative 
effects. Alternatively, they may each 
cause distinct types or levels of dam-
age that then interact to make sunlight 
a potent carcinogen. This is a complex 
issue even with respect to a single dam-
age response such as mutagenesis. Even 
though, as mentioned, each waveband 
likely contributes to mutagenesis, there 
are probably mechanistic differences, 
with dissimilar final contributions to 
carcino genesis. Improvements in the 
prevention and therapy of skin can-
cer require a deeper understanding of 
these issues.
Features affecting sunlight-induced skin 
carcinogenesis: it’s all about position
An important consideration is the posi-
tion in the skin where mutations form. 
Cancers arise from dividing cells rather 
than from cells that are fully differen-
tiated and no longer able to divide. 
Essential characteristics of cancer cells 
are that they are capable of uncontrolled 
cell division and are not fully differen -
tiated. It is more likely that a cell capable 
of dividing will transform into a tumor 
than that a fully differentiated cell will 
regain the capacity of unlimited divi-
sion. Nonmelanoma skin cancers are 
derived from keratinocytes capable of 
division. These cells are located in the 
basal layer of the epidermis and even 
deeper within hair follicles. Therefore, 
to cause a skin cancer in humans, sun-
light must produce mutations in the basal 
layer; mutations at the surface of the skin 
are unlikely to make a large contribution 
to skin carcinogenesis. Because UVA is 
about 20 times more abundant than UVB 
in sunlight and penetrates more deeply 
into the skin, it has been estimated that 
100 times more UVA radiation than UVB 
reaches the dermis (Lim et al., 2001).
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